Get the Stockscreener App
4.775
4.69%
-0.235
After Hours:
4.78
0.005
+0.10%
Personalis Inc Stock (PSNL) Latest News
abrdn plc Invests $1.72 Million in Personalis, Inc. (NASDAQ:PSNL) - MarketBeat
Understanding the Risks of Investing in Personalis Inc (PSNL) - Knox Daily
Wall Street analysts’ outlook for Personalis Inc (PSNL) - SETE News
Should You Expect A Quick Recovery From Personalis Inc (NASDAQ: PSNL) After -35.08% Decline From High? - Marketing Sentinel
BlackRock, Inc.'s Strategic Acquisition of Personalis Inc. Shares - GuruFocus.com
Personalis Inc (PSNL) is a good investment, but the stock may be overvalued - US Post News
Needham analysts upgrades a Buy rating for Personalis Inc (PSNL) - Knox Daily
Personalis, Inc. (NASDAQ:PSNL) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny - Simply Wall St
FY2024 EPS Estimates for Personalis Lowered by HC Wainwright - MarketBeat
Analysts Issue Forecasts for Personalis FY2029 Earnings - MarketBeat
FY2024 EPS Estimates for Personalis Reduced by HC Wainwright - Defense World
Personalis price target lowered to $8 from $11 at H.C. Wainwright - MSN
Brokers Set Expectations for Personalis FY2029 Earnings - Defense World
Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference - Marketscreener.com
Precision Oncology Leader Personalis Takes Center Stage at Major Healthcare Summit - StockTitan
Personalis stock price target cut to $8 by H.C. Wainwright - MSN
Personalis (NASDAQ:PSNL) Given New $8.00 Price Target at HC Wainwright - Defense World
Personalis Stock: A Deep Dive Into Analyst Perspectives (7 Ratings) - Benzinga
HC Wainwright Cuts Personalis (NASDAQ:PSNL) Price Target to $8.00 - MarketBeat
Personalis (PSNL) Upgraded to Buy: Here's Why - Yahoo Finance
Personalis, Inc. (NASDAQ:PSNL) Stock Position Increased by Barclays PLC - Defense World
Researchers find ctDNA test predicts lung cancer outcomes in study - Yahoo Finance
New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer - sharewise
Catherine Wood's Strategic Acquisition of Personalis Inc Shares - GuruFocus.com
Personalis Lung Cancer Test Shows 100% Detection Rate in Breakthrough Study - StockTitan
Personalis (NASDAQ:PSNL) Stock Price Expected to Rise, Lake Street Capital Analyst Says - Defense World
Personalis stock target lifted, retains buy on impressive performance By Investing.com - Investing.com Canada
Personalis (NASDAQ:PSNL) Price Target Raised to $9.00 - MarketBeat
Personalis stock target lifted, retains buy on impressive performance - Investing.com India
Personalis (NASDAQ:PSNL) Earns Buy Rating from HC Wainwright - MarketBeat
Needham & Company LLC Reaffirms "Buy" Rating for Personalis (NASDAQ:PSNL) - MarketBeat
Geode Capital Management LLC Buys 83,068 Shares of Personalis, Inc. (NASDAQ:PSNL) - Defense World
Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue - The Bakersfield Californian
Personalis Beats 2024 Revenue Guidance with 15% Growth, Secures Moderna Partnership - StockTitan
Barclays PLC Buys 20,444 Shares of Personalis, Inc. (NASDAQ:PSNL) - Defense World
Personalis, Inc. (NASDAQ:PSNL) Stake Raised by State Street Corp - Defense World
Jane Street Group LLC Increases Stock Position in Personalis, Inc. (NASDAQ:PSNL) - Defense World
Personalis, Inc. (NASDAQ:PSNL) Stock Position Reduced by Stifel Financial Corp - Defense World
Personalis, Inc. Amends Sales Agreement with Piper Sandler & Co. and BTIG - Defense World
The 16% return this week takes Personalis' (NASDAQ:PSNL) shareholders one-year gains to 159% - Yahoo Finance
Grail (NASDAQ:GRAL) & Personalis (NASDAQ:PSNL) Financial Contrast - Defense World
Local vaccine biotech secures $50 million Merck investment - The Business Journals
1.05%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):